Pulido Marina R, García-Quintanilla Meritxell, Gil-Marqués M Luisa, McConnell Michael J
Biomedical Institute of Seville/University Hospital Virgen del Rocío, Seville, Spain.
Biomedical Institute of Seville/University Hospital Virgen del Rocío, Seville, Spain.
Drug Discov Today. 2016 Mar;21(3):465-72. doi: 10.1016/j.drudis.2015.11.014. Epub 2015 Dec 12.
The lack of new compounds in the antibiotic development pipeline together with the increasing incidence of infections caused by antibiotic-resistant bacteria on a global scale represents an alarming public health problem. Advances in genomic, transcriptomic and proteomic technologies permit the characterization of bacterial physiology at an unprecedented scale, and thus can facilitate the identification of bacterial factors that could serve as targets for the development of new antibiotics. Recent studies employing these technologies have permitted the elucidation of key components in multiple bacterial processes such as bacterial survival, persistence in the host and infection. The continued use of these approaches and the incorporation of emerging omics technologies hold great potential in elucidating high value targets for antibiotic development.
抗生素研发流程中缺乏新化合物,加之全球范围内由耐抗生素细菌引起的感染发病率不断上升,这是一个令人担忧的公共卫生问题。基因组学、转录组学和蛋白质组学技术的进步使以前所未有的规模对细菌生理学进行表征成为可能,因此有助于识别可作为新抗生素开发靶点的细菌因子。最近使用这些技术的研究已经能够阐明多个细菌过程中的关键成分,如细菌存活、在宿主体内的持续存在和感染。持续使用这些方法并纳入新兴的组学技术,在阐明抗生素开发的高价值靶点方面具有巨大潜力。